Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 2/20 | 0.54 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 2/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581477 | 1.00 | NR3C2 (0.54) | NR3C2NUDT1HDAC6HDAC8HDAC1 | |
| SCHEMBL4580276 | 0.79 | IDH1 (0.53) | NR3C2NUDT1HDAC6HDAC8HDAC1 | |
| SCHEMBL4580277 | 0.79 | IDH1 (0.53) | NR3C2NUDT1HDAC6HDAC8HDAC1 | |
| SCHEMBL4582161 | 0.79 | IDH1 (0.46) | NR3C2NUDT1HDAC6HDAC8HDAC1 | |
| SCHEMBL4582156 | 0.79 | IDH1 (0.46) | NR3C2NUDT1HDAC6HDAC8HDAC1 | |
| SCHEMBL4580268 | 0.79 | NUDT1 (0.46) | NUDT1HDAC6HDAC8PIK3C3IDH1 | |
| SCHEMBL2369782 | 0.79 | PIK3CD (0.57) | PIK3CDPIK3CAATRATRIP | |
| SCHEMBL20797866 | 0.79 | PIK3CD (0.57) | PIK3CDPIK3CAATRATRIP | |
| SCHEMBL2369785 | 0.79 | PIK3CD (0.57) | PIK3CDPIK3CAATRATRIP | |
| SCHEMBL4582373 | 0.79 | CDK2 (0.52) | NR3C2NUDT1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323464-B2 | Pyridine and pyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | disclosed |
| EP-1448555-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | Celltech R & D Limited (GB) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045941-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | ROR1, MAPK1, IRAK1 | NR3C2 787/4885NUDT1 762/4885HDAC6 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.